Orphan Drug Status for Sirolimus for Non-Infectious Uveitis - MPR

Links shared publicly online about this topic.

0
total visits

Orphan Drug Status for Sirolimus for Non-Infectious Uveitis - MPR

Santen Inc. announced that the FDA has granted orphan drug designation for sirolimus (DE-109) for the treatment of chronic/refractory anterior non-infectious uveitis, non-infectious intermediate uveitis, non-infectious panuveitis, and non-infectious uveitis affecting the posterior segment of the eye.

View full resource at empr.com

Tags: Eye, Drug, FDA

Most Recently Shared on November 11, 2011 at 2:32 pm By:

MPR

Orphan Drug Status for Sirolimus for Non-Infectious #Uveitis http://t.co/vLl947Hz

6 months ago...

Retweet

Favorite

European Commission grants orphan drug designation for sirolimus for chronic noninfectious uveitis

osnsupersite.com — “EMERYVILLE, Calif. — The European Commission has granted orphan drug status for the use of the sirolimus drug DE-109 in the treatment of chronic” View full resource at osnsupersite.com

Most Recently Shared on September 9, 2011 at 6:30 pm By:

The OSN SuperSite Health News

European Commission grants orphan drug designation for #sirolimus for chronic noninfectious #uveitis http://ht.ly/6pYW5

8 months ago...

Retweet

Favorite

EC grants orphan drug status for Santen's sirolimus to treat chronic non-infectious uveitis

news-medical.net — “Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. today announced the European Commission (EC) has granted orphan drug status for sirolimus (DE-109) for the treatment of chronic non-infectious uveitis.” View full resource at news-medical.net